

Date: 2<sup>nd</sup> November, 2021

**To**  
**The Manager**  
**Dept of Corporate Services**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers**  
**Dalal Street, Mumbai-400001**  
**Scrip Code: 511 509**

Dear Sir/Madam,


**Sub: Outcome of Board Meeting-Reg.**

**Ref:** Regulation 30 & other applicable Regulations of SEBI (LODR) Regulations, 2015.

We wish to inform you that the Board of Directors of the Company, in their just concluded meeting, inter-alia, transacted the following items of business:

1. Approved the Un-Audited Standalone Financial Results for the Second Quarter and half year ended 30<sup>th</sup> September, 2021 as recommended by the Audit committee and Reviewed by the Statutory Auditors.
2. Approved the Un-Audited Consolidated Financial Results for the Second Quarter and half year ended 30<sup>th</sup> September, 2021 as recommended by the Audit committee and Reviewed by the Statutory Auditors.
3. Approved the resignation of Mr. K.T.V. Kaladhar (DIN: 08450361), to the office of Director & CFO of the Company with effect from Wednesday, i.e. 3<sup>rd</sup> November, 2021 due to personal reasons.

The Board of Directors has placed on record its sincere appreciation for Mr. K.T.V. Kaladhar for his valuable services, guidance and contribution to the Company during his tenure as a member of the Board and wishes him very best in his future endeavors.



4. Based on the recommendation of the Nomination & Remuneration Committee the Board of Directors have appointed Mr. K. Sri Kalyan (DIN: 03137506) as an Additional Director (Whole Time Director) of the Company for a period of 5 (five) years with effect from Wednesday, i.e. 3<sup>rd</sup> November, 2021 subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting.

Further, in accordance with the circular dated 20<sup>th</sup> June, 2018, issued by the Stock Exchanges, he is not debarred from holding office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

5. Based on the recommendation of the Nomination & Remuneration Committee the Audit Committee and Board of Directors have approved the appointment of Mr. K. Sri Kalyan as Chief Financial Officer of the Company (CFO) with effect from Wednesday, i.e. 3<sup>rd</sup> November, 2021.

6. Change in Authorisation under regulation 30 (5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the contact details of the Key Managerial Personnel ("KMP") who have been severally authorized by Board of Directors of the Company with effect from Wednesday i.e. 3<sup>rd</sup> November, 2021, for the purpose of determining materiality of an event or information to the Stock Exchanges from time to time under the said regulation is as follows:

Name of the KMP	Designation	Contact Details
Mr. M. Kalyan Ram	Whole Time Director	Email: <a href="mailto:investors@vivobio.com">investors@vivobio.com</a> Phone: 040-2331 3288
Mr. K. Sri Kalyan	Whole Time Director & CFO	Email: <a href="mailto:investors@vivobio.com">investors@vivobio.com</a> Phone: 040-2331 3288
Mr. A. Karthik	Company Secretary & Compliance Officer	Email: <a href="mailto:Karthik@vivobio.com">Karthik@vivobio.com</a> Phone: 040-2331 3288



The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/1015 dated 09th September 2015; including the brief profile of the above Directors is enclosed in **Annexure-A** to this letter.

A copy of this letter is being hosted on the Company's website at [www.vivobio.com](http://www.vivobio.com).

The meeting commenced at 6.45 P.M and concluded at 7.30 P.M.

This is for your information and records.

Thanking you,

Yours faithfully,

**For Vivo Bio Tech Limited**

*A. Karthik*


**A.Karthik**  
Company Secretary



**Annexure-A**

**Details of Mr. K. Sri Kalyan**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	<b>Reason for change viz. appointment, resignation, removal, death or otherwise;</b>	Appointment of Mr. K. Sri Kalyan (DIN: 03137506) as an Additional Whole Time Director & CFO of the Company.
2.	<b>Date of appointment/cessation (as applicable) &amp; term of appointment;</b>	Appointment with effect from 3 <sup>rd</sup> November, 2021 for a period of 5 years subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting.
3.	<b>Brief profile (in case of appointment);</b>	He is a Post Graduate from prestigious SP Jain Center of Management and brings in a total of 20 years of rich and diverse experience to the board. He started his career with Tecumseh Products Company and worked on launching various new products in Indian market. Subsequently, he worked in Virinchi Health care in Projects & Operations division for their flag ship multi-specialty 600 bed hospital. He brings to Vivo Bio, rich and diverse experience cutting across Manufacturing, Statistical Quality Control, Project & Operations Management, Bio Tech - Test Facility Management of Health Care.
4.	<b>Qualifications</b>	B.E (Osmania University) & MBA ( SP Jain Center of Management)
5.	<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	None of the Directors/ Key Managerial Personnel of the Company/ their relatives are in any way related or interested, financially or otherwise.



**Details of Mr. K.T.V. Kaladhar (DIN: 08450361)**

Sl. No.	Particulars	Details
1.	<b>Reason for change viz. appointment, resignation, removal, death or otherwise;</b>	Resignation of Mr. K.T.V. Kaladhar to the office of Director & CFO of the Company due to personal reasons.
2.	<b>Date of appointment/cessation (as applicable) &amp; term of appointment;</b>	Wednesday, 3 <sup>rd</sup> November, 2021
3.	<b>Brief profile (in case of appointment);</b>	Not Applicable
4.	<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	Not Applicable





*M. K. M.*

S.No.	PARTICULARS	UNAUDITED STAND ALONE FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30TH SEPTEMBER, 2021						Rs. in Lacs	
		QUARTER ENDED			HALF YEAR ENDED			Year Ended	
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021	Audited	
I	Revenue from operations	1017.45	1299.09	1466.53	2316.54	2,381.93	5177.52		
II	Other Income	2.39	22.07	0.00	24.47	0.00	7.87		
III	<b>Total Income</b>	<b>1019.84</b>	<b>1321.16</b>	<b>1466.53</b>	<b>2341.01</b>	<b>2381.93</b>	<b>5185.38</b>		
IV	<b>Expenses</b>	<b>(186.01)</b>	<b>201.72</b>	<b>(101.32)</b>	<b>15.71</b>	<b>(10.70)</b>	<b>(269.86)</b>		
	a) Increase/(decrease) in stock in trade and WIP	0.00	0.00	0.00	0.00	0.00	0.00		
	b) Consumption of Raw materials	233.98	131.38	197.96	365.36	321.19	990.56		
	c) Purchase of traded goods	203.44	219.15	258.22	422.58	415.27	856.99		
	d) Employees Cost	173.86	178.71	125.90	352.57	252.32	559.14		
	e) Depreciation and amortisation	106.38	85.97	102.97	192.35	173.33	352.99		
	f) Finance Cost	381.61	285.80	512.91	667.40	768.79	1833.38		
	g) Administrative Expenditure	<b>913.24</b>	<b>1102.72</b>	<b>1096.64</b>	<b>2015.97</b>	<b>1920.20</b>	<b>4323.20</b>		
	<b>Total</b>	<b>106.60</b>	<b>218.44</b>	<b>369.89</b>	<b>325.04</b>	<b>461.73</b>	<b>862.18</b>		
V	Profit Before Tax (III-IV)	0.00	0.00	0.00	0.00	0.00	0.00		
	Exceptional Item	106.60	218.44	369.89	325.04	461.73	862.18		
VI	Profit Before Tax	106.60	218.44	369.89	325.04	461.73	862.18		
VII	Tax Expense	30.30	50.57	73.99	80.88	92.35	135.76		
	a. Current Tax	48.59	44.55	80.45	93.13	56.17	157.97		
	b. Deferred tax	78.89	95.12	154.43	174.01	148.51	293.74		
	<b>Total Tax Expense</b>	<b>27.71</b>	<b>123.32</b>	<b>215.45</b>	<b>151.03</b>	<b>313.21</b>	<b>568.44</b>		
	<b>Net Profit After Tax (V-VI)</b>								
VIII	Other Comprehensive Income								
	a. Items that will be reclassified to profit or loss (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00		
IX	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>27.71</b>	<b>123.32</b>	<b>215.45</b>	<b>151.03</b>	<b>313.21</b>	<b>568.44</b>		
X	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1420.45	1420.45	1288.75	1420.45	1288.75	1341.95		
XI	<b>Earnings per equity share:</b>								
	1) Basic	0.20	0.87	1.67	1.06	2.43	4.24		
	2) Diluted	0.19	0.83	1.67	1.02	2.43	4.20		

Vivo Bio Tech Ltd  
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate  
 Road No.1, Banjara Hills, Hyderabad-500034  
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
 Your Drug Discovery Partner

Particulars		Standalone Cash Flow Statement for the Half Year Ended 30th September, 2021			Rs. In Lacs		
		As at 30.09.2021	As at 30.09.2020	As at 31.03.2021	As at 31.03.2021	As at 31.03.2021	As at 31.03.2021
		Un-Audited	Un-Audited	Audited			
<b>A.</b>	<b>Cash Flow from Operating Activities:</b>						
	Net Profit/ (Loss) before taxation and extraordinary items	325.04	461.73	862.18			
	<b>Adjustments for:</b>						
	Depreciation	-	252.32	559.14			
	Amortised Expenses	352.57	173.33	-			
	Interest expenses	192.35	-	352.99			
	Operating Profit before Working Capital Changes	<b>869.96</b>	<b>887.38</b>	<b>1,774.31</b>			
	<b>Working Capital Changes</b>						
	Trade and other receivables Including Inventory	(474.84)	62.25	145.06			
	Trade and Other payables	(87.58)	(261.77)	136.87			
	<b>Cash Generated from Operations</b>	<b>307.54</b>	<b>687.86</b>	<b>2,056.24</b>			
	Interest paid	192.35	173.33	352.99			
	Taxation for the year	174.01	92.35	293.74			
	<b>Net Cash from Operating Activities</b>	<b>(58.82)</b>	<b>422.18</b>	<b>1,409.51</b>			
<b>B.</b>	<b>Cash Flow from Investing Activities:</b>						
	Purchase of Fixed Assets	(93.55)	(700.89)	(2,282.18)			
	Investment		-	-			
	<b>Net Cash used in Investing Activities</b>	<b>(93.55)</b>	<b>(700.89)</b>	<b>(2,282.18)</b>			
<b>C.</b>	<b>Cash Flow From Financial Activities:</b>						
	Proceeds from Equity Shares	234.06	(0.00)	382.05			
	Net Proceeds from Long Term Borrowings	(51.56)	647.19	501.27			
	<b>Net Cash used in Financing Activities</b>	<b>182.50</b>	<b>647.19</b>	<b>883.32</b>			
	Net increase in cash and cash equivalents	30.14	368.48	10.65			
	Cash and Cash equivalents as at Beginning of the Year	109.71	99.05	99.05			
	<b>Cash and Cash equivalents as at 30.09.2021</b>	<b>139.85</b>	<b>467.54</b>	<b>109.71</b>			



Vivo Bio Tech Ltd  
8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate  
Road No.1, Banjara Hills, Hyderabad-500034  
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

S.No.	PARTICULARS	UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QTR AND HALF YEAR ENDED 30TH SEPTEMBER, 2021						Rs. in Lacs	
		QUARTER ENDED		HALF YEAR ENDED		Year Ended		Audited	Audited
		30.09.2021 Un-Audited	30.06.2021 Un-Audited	30.09.2020 Un - Audited	30.09.2021 Un-Audited	30.09.2020 Un - Audited	31.03.2021		
I	Revenue from operations	1,016.83	1299.71	1466.53	2,316.54	2381.93	5177.52		
II	Other Income	3.01	22.07	0.00	25.09	0.00	7.87		
III	<b>Total Income</b>	<b>1019.84</b>	<b>1321.78</b>	<b>1466.53</b>	<b>2341.63</b>	<b>2381.93</b>	<b>5185.38</b>		
IV	<b>Expenses</b>	(115.67)	131.38	(101.32)	15.71	(10.70)	(269.86)		
	a) Increase/(decrease) in stock in trade and WIP	-	0.00	0.00	0.00	0.00	0.00		
	b) Consumption of Raw materials	163.63	201.72	197.96	365.36	321.19	990.56		
	c) Purchase of traded goods	203.44	219.15	258.22	422.58	415.27	856.99		
	d) Employees Cost	66.77	178.71	130.92	352.57	257.34	559.14		
	e) Depreciation and amortisation	106.38	85.97	102.97	192.35	173.33	353.00		
	f) Finance Cost	488.70	285.80	512.91	667.40	768.80	1833.59		
	g)Administrative Expenditure	913.24	1102.72	1101.66	2015.97	1925.22	4323.41		
V	<b>Total</b>	<b>106.60</b>	<b>219.06</b>	<b>364.86</b>	<b>325.66</b>	<b>456.70</b>	<b>861.97</b>		
VI	Profit Before Tax & Exceptional Item (III-IV)	0.00	0.00	0.00	0.00	0.00	0.00		
VII	Exceptional Item	106.60	219.06	364.86	325.66	456.70	861.97		
	Profit Before Tax	0.00	0.00	0.00	0.00	0.00	0.00		
	Tax Expense	30.30	50.57	73.99	80.88	92.35	135.76		
	a. Current Tax	48.59	44.55	80.45	93.13	56.17	157.97		
	b. Deferred tax	78.89	95.12	154.43	174.01	148.51	293.74		
	<b>Total Tax Expense</b>	<b>27.71</b>	<b>123.94</b>	<b>210.43</b>	<b>151.65</b>	<b>308.19</b>	<b>568.23</b>		
VIII	<b>Net Profit After Tax (V-VI)</b>	0.00	0.00	0.00	0.00	0.00	0.00		
IX	Minority Interest								
	Other Comprehensive Income								
	a. Items that will be reclassified to profit or loss (Net of Tax)	0	0	0.00	0.00	0.00	0.00		
X	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>27.71</b>	<b>123.94</b>	<b>210.43</b>	<b>151.65</b>	<b>308.19</b>	<b>568.23</b>		
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,420.45	1420.45	1288.75	1420.45	1288.75	1341.95		
XII	<b>Earnings per equity share:</b>								
	1)Basic	0.20	0.87	1.63	1.07	2.39	4.23		
	2)Diluted	0.19	0.84	1.63	1.02	2.39	4.19		

*M. Madhavi*



Vivo Bio Tech Ltd  
 8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate  
 Road No.1, Banjara Hills, Hyderabad-500034  
 E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
 Your Drug Discovery Partner

Particulars		Consolidated Cash Flow Statement for the Half Year Ended 30th September, 2021			Rs. In Lacs		
		As at 30.09.2021	As at 30.09.2020	As at 31.03.2021	Un-Audited	Un-Audited	Audited
<b>A.</b>	<b>Cash Flow from Operating Activities:</b>						
	Net Profit/ (Loss) before taxation and extraordinary items	325.66	456.70	861.97			
	<b>Adjustments for:</b>						
	Depreciation	352.57	257.34	559.14			
	Amortised Expenses						
	Interest expenses	192.35	173.33	353.00			
	Operating Profit before Working Capital Changes	<b>870.57</b>	<b>887.37</b>	<b>1,774.11</b>			
	<b>Working Capital Changes</b>						
	Trade and other receivables Including Inventory	(474.84)	101.19	153.33			
	Trade and Other payables	(87.58)	(261.95)	136.90			
	<b>Cash Generated from Operations</b>	<b>308.16</b>	<b>726.62</b>	<b>2,064.34</b>			
	Interest paid	192.35	173.33	353.00			
	Taxation for the year	174.01	92.35	293.74			
	<b>Net Cash from Operating Activities</b>	<b>(58.20)</b>	<b>460.94</b>	<b>1,417.60</b>			
<b>B.</b>	<b>Cash Flow from Investing Activities:</b>						
	Purchase of Fixed Assets	(93.55)	(700.89)	(2,282.18)			
	Investment						
	<b>Net Cash used in Investing Activities</b>	<b>(93.55)</b>	<b>(700.89)</b>	<b>(2,282.18)</b>			
<b>C.</b>	<b>Cash Flow From Financial Activities:</b>						
	Proceeds from Equity Shares	234.06	(0.00)	382.05			
	Net Proceeds from Long Term Borrowings	(51.56)	611.46	496.21			
	<b>Net Cash used in Financing Activities</b>	<b>182.50</b>	<b>611.46</b>	<b>878.26</b>			
	<b>Net increase in cash and cash equivalents</b>	<b>30.76</b>	<b>371.52</b>	<b>13.68</b>			
	Cash and Cash equivalents as at Beginning of the Year	116.54	102.86	102.86			
	Cash and Cash equivalents as at 30.09.2021	<b>147.30</b>	<b>474.38</b>	<b>116.54</b>			

*M. S.*



Vivo Bio Tech Ltd  
8-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate  
Road No.1, Banjara Hills, Hyderabad-500034  
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163

**Vivo Bio Tech Ltd.**  
Your Drug Discovery Partner

Statement of Assets and Liabilities at at 30th September, 2021		Rs. In Lacs			
		Standalone		Consolidated	
Sl.No	Particulars	As At	As At	As At	As At
		30.09.2021	31.03.2021	30.09.2021	31.03.2021
		Un-Audited	Audited	Un-Audited	Audited
I	<b>ASSETS</b>				
	<b>Non-Current Assets</b>				
	<b>Fixed Assets</b>				
	Property, Plant and Equipment	3,570.97	3,735.03	3,906.99	4,071.05
	Capital Work-In-Progress	53.23	32.49	53.23	32.49
	Intangible Assets	1,017.92	1,133.62	1,017.92	1,133.62
	<b>Financial Assets</b>				
	Non-Current Investments	4.00	4.00		
	Long Term Loans and Advances	2.09	4.55	4.03	6.49
	Deferred Tax Asset				
	<b>Total Non-Current Assets</b>	<b>4,648.21</b>	<b>4,909.69</b>	<b>4,982.17</b>	<b>5,243.65</b>
	<b>Current Assets</b>				
	Inventories	1,312.02	1,327.73	1,312.02	1,327.73
	<b>Financial Assets</b>				
	Trade Receivables	830.69	729.30	830.69	729.30
	Cash and cash equivalents	139.85	109.71	147.30	116.54
	Short term loans and advances	880.11	594.83	760.89	475.61
	Other current assets	165.83	59.49	165.83	59.49
	<b>Total Current Assets</b>	<b>3,328.49</b>	<b>2,821.05</b>	<b>3,216.73</b>	<b>2,708.67</b>
	<b>TOTAL ASSETS</b>	<b>7,976.69</b>	<b>7,730.74</b>	<b>8,198.90</b>	<b>7,952.32</b>
II	<b>EQUITY AND LIABILITIES</b>				
	<b>Equity</b>				
	Equity Share Capital	1,420.45	1,341.95	1,420.45	1,341.95
	Other Equity	3,149.87	2,769.59	3,149.00	2,768.09
	Money Received Against Share Warrants	68.96	142.65	68.96	142.65
	<b>Total Equity</b>	<b>4,639.29</b>	<b>4,254.19</b>	<b>4,638.41</b>	<b>4,252.70</b>
	<b>Liabilities</b>				
	<b>Non Current liabilities</b>				
	<b>Financial Liabilities</b>				
	Borrowings	1,190.75	1,242.31	1,413.39	1,464.95
	Deferred Tax Liabilities(Net)	96.27	47.83	51.08	47.83
	Long term provisions	51.08	3.14	96.27	3.14
	<b>Total Non Current Liabilities</b>	<b>1,338.10</b>	<b>1,293.28</b>	<b>1,560.74</b>	<b>1,515.92</b>
	<b>Current Liabilities</b>				
	<b>Financial Liabilities</b>				
	Borrowings	1,516.08	1,630.71	1,516.08	1,630.71
	Trade Payable & Other Current Liabilities	99.08	138.83	99.08	138.83
	Provisions	384.14	413.73	384.58	414.17
	<b>Toatal Current Liabilities</b>	<b>1,999.30</b>	<b>2,183.26</b>	<b>1,999.74</b>	<b>2,183.71</b>
	<b>Total Equity &amp; Liabilities</b>	<b>7,976.69</b>	<b>7,730.74</b>	<b>8,198.90</b>	<b>7,952.32</b>

Place: Hyderabad  
Date: 2nd November, 2021

For Vivo Bio Tech Ltd



*M. Kalyan Ram*  
Kalyan Ram Mangipudi  
Whole Time Director  
DIN:02012580

**Notes:**

1. The above Un-Audited Financial Results for the Quarter and Half year ended 30<sup>th</sup> September, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 2<sup>nd</sup> November, 2021. These results have been subjected to limited review carried out by the Statutory Auditors.
2. The above Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
4. An Extract of the detailed format of Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 will be published in Newspaper.
5. The above financial results are available on the stock exchange website [www.bseindia.com](http://www.bseindia.com) and company's website [www.vivobio.com](http://www.vivobio.com).
6. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

For Vivo Bio Tech Limited



Place: Hyderabad  
Date: 2<sup>nd</sup> November, 2021



**M. Kalyan Ram**  
Whole Time Director  
DIN: 02012580



**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

**Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

To the Board of Directors  
Vivo Bio Tech Limited,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Vivo Bio Tech Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019

The preparation of "the Statement", which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

*ecaf*





**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates  
Chartered Accountants  
Firm's Registration No: 016016S

*M. Mohana Saradhi*

M. Mohana Saradhi  
Partner  
M.No. 244686  
UDIN: 21244686AAAADK8563



Place: Hyderabad  
Date: 02.11.2021



**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly Unaudited Ind AS Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors  
Vivo Bio Tech Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Vivo Bio Tech Limited (the "Holding Company") and its subsidiaries (the "Holding Company" and its subsidiaries together referred to as "the Group"), for the quarter and half year ended 30<sup>th</sup> September, 2021 ("the Statement"), being submitted by the "Holding Company" pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on "the Statement" based on our review.

We conducted our review of "the Statement" in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether "the Statement" is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

*ec. as*





**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

"The Statement" includes the Ind AS financial results of the following entities:

- I. Vivo Bio Labs Private Limited
- II. Vivo Bio Discovery Services Private Limited
- III. Surlogic Life Consultancy Private Limited
- IV. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above and based on the considerations of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We didn't review the interim financial results and other unaudited financial information in respect of 4 subsidiaries, whose interim Ind AS financial results and other financial information reflect total assets of Rs. 222.20 Lakhs as at 30.09.2021 and total revenue of Rs. 0.62 Lakhs, total net profit/(loss) after tax of Rs. 0.62 Lakhs for the period from 01-04-2021 to 30-09-2021, as considered in the consolidated unaudited financial results. These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

*ec.ass*





**P C N & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
Plot No. 12, "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

Our conclusion on the Statement in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management

For P C N & Associates  
Chartered Accountants  
Firm's Registration No: 016016S

*ecaf*



M. Mohana Saradhi  
Partner  
Membership No. 244686  
UDIN: 21244686AAAADL6127

Place: Hyderabad  
Date: 02.11.2021.